Sector BioCryst Pharmaceuticals, Inc.

Aandelen

BCRX

US09058V1035

Biotechnologie & Medisch Onderzoek

Beurs gesloten - 21:00:00 27-10-2026 Variatie 5 dagen Verschil t.o.v. 1 jan (%)
8,100 USD +2,79% Intraday-grafiek van BioCryst Pharmaceuticals, Inc. +2,02% +3,85%
Belangrijkste concurrenten
Verschil (%) Varia. 5d. Evolutie 1 maand Evolutie 3 maanden Var. 1 jan Varia. 1j. Varia. 3j. Varia. 5j. Varia. 10j. Kap.($)
+2,79%+2,02%-5,70%-15,45%+3,85%+10,81%+52,54%-45,75%+87,94% 2,01 mld.
-3,10%-4,19%-12,88%+13,49%+56,09%+32,67%+59,47%+4,36% - 65,28 mld.
+0,33%+0,33%-7,38%-0,89%+9,21%+10,16%+78,07%+225,62%+5.451,77% 54,57 mld.
+0,16%+1,73%+11,70%+13,66%+18,22%+9,89%+102,10%-15,79%+259,62% 53,59 mld.
-0,75%+1,38%+0,44%+27,36%+20,47%+24,89%+50,91%+6,79%+276,63% 45,03 mld.
-1,30%-4,80%+1,44%+12,32%+20,49%+16,05%+114,76%-0,33%+1.015,68% 42,17 mld.
+1,26%-5,26%-9,15%-0,98%+133,80%+221,12%+900,64%+574,95% - 39,42 mld.
-0,74%-4,46%+6,31%+5,54%+9,41%+11,00%+44,65%+4,75%+151,07% 32,71 mld.
+1,11%+15,18%+31,62%+57,08%+47,85%+60,27%+49,33%+3,20%+162,43% 26,5 mld.
+3,18%-6,72%-13,71%+19,44%+46,56%+25,35%-8,75%-60,00% - 24,01 mld.
+0,23%-4,51%-11,63%-4,42%-8,55%-17,91%-4,54%-68,77% - 21,82 mld.
+1,75%-0,74%-19,41%-9,33%-45,44%-42,10%+297,65%+259,70%+590,12% 20,38 mld.
-0,44%+8,25%+8,87%+14,32%+19,97%+12,96%+169,21%+219,94%+2.244,43% 18,93 mld.
+0,44%+13,75%+22,54%+59,98%+79,89%+83,76%+107,91%-16,56%+369,19% 17,06 mld.
-0,58%+8,20%+10,50%+27,73%+36,99%+38,81%+84,70%-16,52%+107,58% 16,69 mld.
+0,37%+1,49%+12,36%+17,09%+49,10%+63,42%+223,51%+206,81%+498,44% 16,13 mld.
+0,29%+4,92%+8,98%-2,99% - - - - - 16,1 mld.
+2,59%+3,03%+3,03%-0,42%+180,86%+161,39%+341,90%+1.405,54%+779,81% 14,75 mld.
-1,77%-5,92%-2,20%-12,45%+13,51%+5,55%+444,25% - - 14,63 mld.
-0,44%+5,05%+6,18%+8,41%+0,42%+0,52%-22,24%-35,05%+127,36% 14,18 mld.
Gemiddelde +0,27%+2,22%+2,10%+11,48%+36,46%+38,35%+162,43%+147,38%+865,86% 27,8 mld.
Gewogen gemiddelde per kap. -0,15%+0,86%+0,59%+12,65%+36,70%+38,68%+159,61%+122,57%+1.227,80%
  1. Beurs
  2. Aandelen
  3. Koers BCRX
  4. Sector BioCryst Pharmaceuticals, Inc.